Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Reconstructing the skeleton with intermittent parathyroid hormone.

E Seeman1, P D Delmas

  • 1Austin and Repatriation Medical Centre, University of Melbourne, VIC., Australia. ego@austin.unimelb.edu.au

Trends in Endocrinology and Metabolism: TEM
|August 16, 2001
PubMed
Summary

This study explores how intermittent administration of parathyroid hormone (PTH) can help restore bone strength in a model of osteoporosis. Osteoporosis treatment typically focuses on slowing bone loss, but PTH may offer a different approach by stimulating new bone formation. The study finds that PTH can increase bone diameter, thicken cortices, and improve trabecular connectivity. These effects are observed in animals with osteoporosis induced by gonadectomy. The results suggest that PTH has anabolic effects that could lead to new treatment strategies for skeletal diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Provision of High Protein Foods Slows the Age-Related Decline in Nutritional Status in Aged Care Residents: A Cluster-Randomised Controlled Trial.

The journal of nutrition, health & aging·2023
Same author

Effect of dietary sources of calcium and protein on hip fractures and falls in older adults in residential care: cluster randomised controlled trial.

BMJ (Clinical research ed.)·2021
Same author

Sex differences in recovery of quality of life 12 months post-fracture in community-dwelling older adults: analyses of the Australian arm of the International Costs and Utilities Related to Osteoporotic Fractures Study (AusICUROS).

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2021
Same author

Systemic mastocytosis identified in two women developing fragility fractures during lactation.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2018
Same author

Bone remodeling markers: so easy to measure, so difficult to interpret.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2015
Same author

Recurrence of bilateral atypical femoral fractures associated with the sequential use of teriparatide and denosumab: a case report.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2015

Area of Science:

  • Endocrinology and metabolic disorders
  • Bone biology and osteoporosis research
  • Pharmacological treatment of skeletal diseases

Background:

Osteoporosis treatment aims to increase bone mass and improve its structural integrity. Current therapies often focus on reducing bone resorption, which limits remodeling and allows for mineralization of existing bone. However, these approaches do not alter the overall architecture of bone. Anabolic agents offer a different strategy by promoting new bone formation. Parathyroid hormone (PTH) is primarily known for its role in increasing calcium levels through bone resorption. Yet, earlier studies suggested PTH could also stimulate bone growth when administered intermittently. This dual effect remains underappreciated despite historical evidence. The mechanism of PTH in bone reconstruction is not fully understood. Limited research has explored how PTH affects both outer and inner bone surfaces. The role of PTH in altering bone diameter and cortical thickness is still being studied. Understanding these effects could lead to new treatment strategies for osteoporosis.

Purpose Of The Study:

Keywords:
PTH osteoporosis treatmentbone reconstruction methodsanabolic bone agentsintermittent hormone therapy

Frequently Asked Questions

Intermittent PTH administration stimulates new bone formation on both periosteal and endosteal surfaces, increasing bone diameter and cortical thickness.

Gonadectomy induces osteoporosis in the study model, allowing researchers to test the effects of PTH on weakened bone structure.

Intermittent administration is necessary to stimulate anabolic effects without triggering excessive bone resorption.

PTH-treated bone shows increased diameter, thicker cortices, and potentially improved trabecular connectivity.

Related Experiment Videos

This study examines the potential of intermittent PTH administration to enhance bone strength and architecture. The goal is to determine how PTH influences bone formation on both periosteal and endosteal surfaces. The focus is on understanding the effects of PTH in a model of osteoporosis induced by gonadectomy. The aim is to clarify how PTH might enlarge bone diameter and increase cortical thickness. Researchers also seek to investigate if PTH can improve trabecular numbers and connectivity. The study explores whether PTH can stimulate new bone formation in a controlled manner. The motivation is to identify a treatment that goes beyond simply slowing bone loss. The ultimate purpose is to assess PTH’s role in reconstructing bone structure and function.

Main Methods:

The study uses a model of osteoporosis induced by gonadectomy in various species. Intermittent administration of PTH is tested to observe its effects on bone architecture. Researchers measure bone diameter, cortical thickness, and trabecular connectivity. They assess changes in periosteal and endosteal bone surfaces. Histological and imaging techniques are used to evaluate new bone formation. The study compares PTH-treated groups with control groups. Data is collected on bone mass and structural parameters. The approach combines pharmacological intervention with structural analysis to determine PTH’s effects.

Main Results:

Intermittent PTH administration increases bone strength by stimulating new bone formation. Bone diameter is enlarged, and cortical thickness is increased. Periosteal and endosteal surfaces show enhanced bone growth. Trabecular numbers and connectivity may also improve. These effects are observed in multiple species with gonadectomy-induced osteoporosis. The results suggest PTH can reconstruct bone architecture. Bone remodeling is stimulated in a way that enhances structural integrity. The findings support the idea that PTH has anabolic effects in bone tissue.

Conclusions:

The authors suggest that intermittent PTH administration may help restore bone strength by promoting new bone formation. The observed effects include increased bone diameter and thicker cortices. The results indicate that PTH can stimulate growth on both outer and inner bone surfaces. The study supports the potential of PTH as an anabolic agent for bone reconstruction. The findings suggest that PTH may improve trabecular connectivity and numbers. The authors propose that PTH could be used to enhance structural integrity in osteoporosis. The evidence supports the idea that PTH has anabolic effects in bone tissue. These findings may lead to new treatment strategies for skeletal diseases.

Bone strength is assessed through measurements of diameter, cortical thickness, and trabecular connectivity using imaging and histological techniques.

The authors suggest that PTH may be used to reconstruct bone architecture and enhance structural integrity in osteoporosis.